On June 5, 2024 QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways (Press release, Qiagen, JUN 5, 2024, View Source [SID1234644137]). The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Genetic research is moving fast, and new target genes are rapidly evolving that are not covered by standard or pre-designed assays. To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform. It enables customers to design and order assays for use on QIAGEN’s digital PCR platform QIAcuity outside of QIAGEN’s comprehensive catalog of over 200 wet-lab validated assays for copy number variations profiling in translational cancer research. Copy number variations (CNVs) are a type of genetic variation where specific segments of the DNA are copied more or fewer times than normal in the genome, potentially affecting susceptibility to diseases and response to treatment.
"As certain copy number variations are associated with cancer, studying them can improve the understanding of how these variations can affect health and the responsiveness to treatments. It is therefore crucial for advancing precision medicine," explained Nitin Sood, Senior Vice President, Head of the Life Science Business Area at QIAGEN. "Our new digital PCR Custom Assay Design Tool in GeneGlobe provides researchers with an innovative and user-friendly tool to design customized assays for QIAcuity tailored to their specific needs, streamlining research and accelerating scientific discovery."
Additional enhancements of GeneGlobe have been launched recently or are currently in development. These include more user-friendly design pages that simplify product selection and a new tool for creating, saving and editing target gene lists, supporting researchers in creating their own panels, even collaboratively. Thanks to a software update, pathway maps from QIAGEN’s Ingenuity Pathway Analysis are now rendered faster. QIAGEN is working on improving the searchability of pathways and pathway relationships and plans to expand the interactivity of pathway diagrams, facilitating the import of selected genes into the GeneGlobe Custom Panel Design tools.
QIAGEN is building a strong pipeline for customization and plans to expand the dPCR Custom Assay Design Tool capabilities to microbial and somatic mutation assays later in 2024. When customers seek higher-order multiplexing or more complex assays, QIAGEN Genomic Services offers expert custom assay design support and assays are made available in GeneGlobe.
About GeneGlobe
QIAGEN’s proprietary research platform GeneGlobe provides researchers with easy access to an extensive range of molecular biology tools, pre-designed assays and customizable design services. The platform streamlines the process of identifying, selecting, and customizing assays, panels and pathway maps tailored to specific research needs while continuously updating its content to ensure researchers stay up to date with the latest advancements in their respective fields.
Learn more about QIAGEN’s GeneGlobe Design and Analysis Hub and the latest advancements at View Source
About QIAcuity
QIAGEN’s digital PCR platform QIAcuity uses nanoplates to disperse a sample over thousands of tiny partitions and then reads the reaction in each one simultaneously to quantify even the faintest signals from DNA and RNA. This enables specific, sensitive, and rapid detection of small copy number changes up to 5-plex.
The highly versatile QIAcuity systems integrate partitioning, thermocycling, and imaging into one workflow, cutting processing times to only two hours from six and are available in one, four and eight-plate versions. While the one-plate version processes up to 384 samples in an eight-hour shift, the eight-plate version processes up to 1,248 samples in the same time period. At the end of 2023, more than 2,000 cumulative instrument placements had been made.